Argonaute Rna Limited

Argonaute Rna Ltd, based in Cardiff, UK, is a small, active company founded nine years ago in 2015. With seven employees and £358,650 in assets, it operates from a real address within the Cardiff Business Technology Centre. The company has ten directors, although no owners are currently listed, which is a bit unusual. It’s an irregular importer, primarily dealing with pharmaceutical products, with its last import activity recorded one month ago in February 2023.

The company’s focus is on research and experimental development within the biotechnology industry, specifically pursuing RNA interference therapies. Its website highlights a “Pulse siRNA” platform, protected by patents, designed to treat life-threatening conditions. Argonaute RNA actively seeks strategic partners and investors to accelerate development, presenting at several industry conferences including RNA Leaders, Basel and the LSX World Congress, London. It even has a team of industry experts, including former leaders from GSK and AstraZeneca.

Financially, Argonaute RNA Ltd’s numbers paint a mixed picture. Current assets have fallen significantly by 54%, dropping to £360,000, while net assets have plummeted 51% to £400,000. Creditors have increased substantially by 230%, reaching £200,000, and bank cash has decreased by a considerable 72%, now sitting at £140,000. The company’s small size—meeting two of three criteria for a small company—allows for flexibility, but the decrease in equity is a concern. The company is exempt from an audit, so the figures are unaudited. The increase in creditors, while potentially reflecting increased business activity, could also indicate challenges in managing short-term liabilities.

Registered in England/Wales under the registration number 09694988, with a registered address at CF24 4AY, Wales, Cardiff, Cardiff Business Technology Centre, Senghennydd Road.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.